PHIO Phio Pharmaceuticals (PHIO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001533040
Cluster · 3 insidersC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about PHIO
Insiders, 180 days
+$69.0K net bought
3 buyers
Phio Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Phio Pharmaceuticals Corp. insiders bought a net $69.0K of stock across 33 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 28, 2026.
- The trade is 11.9% of the 42,000 shares held after it.
- 2 other insiders bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Plott Ronald Todd bought about $5.2K of PHIO on Sep 29, 2026; 2 other insiders bought within 30 days and 9 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 19, 2026.
- The trade is 13.5% of the 37,000 shares held after it.
- 2 other insiders bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Plott Ronald Todd bought about $5.2K of PHIO on Sep 28, 2026; 2 other insiders bought within 30 days and 9 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 15, 2026.
- The trade is 10.1% of the 64,151 shares held after it.
- 2 other insiders bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BRADFORD PATRICIA A bought about $6.6K of PHIO on Sep 24, 2026; 2 other insiders bought within 30 days and 9 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on Aug 18, 2026.
- +5.6% median (-5.0% mean) 90-day return after 20 previous buys.
- The trade is 0.5% of the 364,871 shares held after it.
- 2 other insiders bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, Pres. & CEO Bitterman Robert J bought about $2.1K of PHIO on Sep 22, 2026; 2 other insiders bought within 30 days and 9 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 20.8% of the 57,651 shares held after it.
- 2 other insiders bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BRADFORD PATRICIA A bought about $12.4K of PHIO on Sep 15, 2026; 2 other insiders bought within 30 days and 9 funds added in the latest 13F quarter.33 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$69.0K over 180 days
+$59.1K over 90 days
more than 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 75% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders independently bought a net $69.0K while the stock fell 28% over six months, with no planned sales queued.
What changed in the last 30 days
Sep 30Director Plott Ronald Todd bought $10.3K (2 trades, Sep 28 to Sep 29)
Watch PHIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-60.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PHIO: institutional holders (13F)
13F holdings, latest reported quarter
117,755 sh
$120.7K
114,574 sh
$117.4K
94,262 sh
$96.6K
$51.0K
47,500 sh
$48.7K
Congress trades in PHIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PHIO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PHIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$12.3K position · as of 2026-06-30
0.0%
Nomura Healthcare Fund
$51.2K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$89.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$96.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$16.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$14.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
What changed recently
Intratumoral PH-762 for Cutaneous Carcinoma
2026-09-22 · Active Not Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Robert M. Infarinato
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.2M
$886.0K
$599.7K
-81%
n/a
2024
$387.0K
$384.5K
$105.2K
-77%
n/a
2023
$437.9K
$379.4K
n/a
-94%
n/a
2022
$109.4K
$94.7K
n/a
-86%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $69.0K bought by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PHIO financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2020-01-01 to 2020-12-31
Revenue, TTM PHIO
| FY Dec 2025 | $0 |
| FY Dec 2024 | $0 |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM PHIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PHIO
| FY Dec 2025 | -$8.0M |
| FY Dec 2024 | -$7.1M |
| FY Dec 2023 | -$10.8M |
| FY Dec 2022 | -$12.2M |
| FY Dec 2021 | -$11.9M |
| Jun 2026 | -$4.0M |
| Mar 2026 | -$4.0M |
| Dec 2025 | -$2.1M |
| Sep 2025 | -$2.1M |
| Jun 2025 | -$2.5M |
| Mar 2025 | -$1.3M |
| Dec 2024 | -$1.4M |
| Sep 2024 | -$2.0M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2021-12-31 (54 months older than the period end); equity 2026-06-30
Debt to equity PHIO
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt PHIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-113.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PHIO
| FY Dec 2025 | -69.9% |
| FY Dec 2024 | -114.8% |
| FY Dec 2023 | -116.6% |
| FY Dec 2022 | -70.1% |
| FY Dec 2021 | -76.0% |
| Jun 2026 | -113.7% |
| Mar 2026 | -76.4% |
| Dec 2025 | -69.9% |
| Sep 2025 | -107.6% |
| Jun 2025 | -102.2% |
| Mar 2025 | -76.1% |
| Dec 2024 | -114.8% |
| Sep 2024 | -122.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-100.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PHIO
| FY Dec 2025 | -63.9% |
| FY Dec 2024 | -94.7% |
| FY Dec 2023 | -97.6% |
| FY Dec 2022 | -60.4% |
| FY Dec 2021 | -65.0% |
| Jun 2026 | -100.8% |
| Mar 2026 | -70.9% |
| Dec 2025 | -63.9% |
| Sep 2025 | -91.6% |
| Jun 2025 | -85.4% |
| Mar 2025 | -66.7% |
| Dec 2024 | -94.7% |
| Sep 2024 | -96.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PHIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-117.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PHIO
| FY Dec 2025 | -75.3% |
| FY Dec 2024 | -118.6% |
| FY Dec 2023 | -116.4% |
| FY Dec 2022 | -69.5% |
| FY Dec 2021 | -75.8% |
| Jun 2026 | -117.8% |
| Mar 2026 | -81.9% |
| Dec 2025 | -75.3% |
| Sep 2025 | -114.2% |
| Jun 2025 | -107.4% |
| Mar 2025 | -79.3% |
| Dec 2024 | -118.6% |
| Sep 2024 | -125.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PHIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$3.1M
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
Enterprise value PHIO
| FY Dec 2025 | -$9.7M |
| FY Dec 2024 | -$3.5M |
| FY Dec 2023 | $8.2M |
| FY Dec 2022 | $545.9M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | -$1.1M |
| Mar 2026 | -$2.9M |
| Dec 2025 | -$9.7M |
| Sep 2025 | $3.5M |
| Jun 2025 | $500.7K |
| Mar 2025 | -$7.1M |
| Dec 2024 | -$3.5M |
| Sep 2024 | -$2.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-123.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield PHIO
| FY Dec 2025 | -70.7% |
| FY Dec 2024 | -374.5% |
| FY Dec 2023 | -64.3% |
| FY Dec 2022 | -2.2% |
| FY Dec 2021 | -0.8% |
| Jun 2026 | -102.5% |
| Mar 2026 | -75.6% |
| Dec 2025 | -70.7% |
| Sep 2025 | -51.3% |
| Jun 2025 | -63.4% |
| Mar 2025 | -102.7% |
| Dec 2024 | -374.5% |
| Sep 2024 | -273.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PHIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M |
| EPS (diluted) | n/a | -9.08 | -46.76 | -10.10 |
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M |
| Cash | $21.0M | $5.4M | $8.5M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
PHIO Stock Sonar score 6/7 axes
Find similar shapesComparePHIO ranks highest on financial health (99th percentile) and insider conviction (81st), and lowest on growth (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PHIO filings, in plain words
Are Phio Pharmaceuticals insiders buying or selling PHIO?
In the 180 days to 2026-10-28, Phio Pharmaceuticals insiders were net buyers, a net $69.0K across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-28, Phio Pharmaceuticals insiders were net buyers of PHIO, a net $69.0K across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
